*Applications will be reviewed on a rolling-basis.
A postdoctoral fellowship opportunity is currently available with the Division of Genetic and Molecular Toxicology, National Center for Toxicological Research (NCTR) of the U.S. Food and Drug Administration (FDA) Jefferson Laboratories Campus located in Jefferson, Arkansas.
Research efforts will include participation in multi-disciplinary efforts in a nationally recognized training program in support of the FDA’s mission and be trained to conduct fundamental and applied research designed to elucidate mechanisms of toxicity and support risk-assessment for chemicals of interest to the FDA. Through these fellowships, the selected participants will have the opportunity to learn and apply different molecular tools, and genotoxicity and mutagenicity assays to address public health-related issues and gain experience in their use geared towards the advancement of regulatory science. While participating in the projects, the participants will be actively encouraged to present the research at internal and external conferences and publish the findings in peer-reviewed journals.
The selected participant will be trained under Dr. Yiying Wang and her team to apply an in vitro model that combines human embryonic stem cells (hESCs) as an in vitro surrogate for the developing embryo with a placental barrier to evaluate the risks associated with placental drug transfer. Collaborative activities include: 1) differentiating human pluripotent stem cells into cardiomyocytes or neurons for use in evaluating risks associated with placental drug transfer, and measuring a panel of general toxicity and cardiac- and neuro- developmental toxicity endpoints; 2) following completion of toxicology studies, analyzing gene expression and epigenetic profiles, as well as mutation induction in response to drug exposure.
Anticipated Appointment Start Date: November 1, 2021; start date is flexible
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Jefferson, Arkansas, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.
FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:
- Non-employee nature of the ORISE appointment;
- Prohibition on ORISE Fellows performing inherently governmental functions;
- Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
- The fact that research materials and laboratory notebooks are the property of the FDA;
- ORISE fellow’s obligation to protect and not to further disclose or use non-public information.
If you have questions, send an email to ORISE.FDA.NCTR@orau.org. Please include the reference code (FDA-NCTR-2021-0013) for this opportunity in your email.